TY - JOUR
T1 - International union of basic and clinical pharmacology. Cx. Classification of receptors for 5-hydroxytryptamine; pharmacology and function
AU - Barnes, Nicholas M.
AU - Ahern, Gerard P.
AU - Becamel, Carine
AU - Bockaert, Joël
AU - Camilleri, Michael
AU - Chaumont-Dubel, Severine
AU - Claeysen, Sylvie
AU - Cunningham, Kathryn A.
AU - Fone, Kevin C.
AU - Gershon, Michael
AU - Di Giovanni, Giuseppe
AU - Goodfellow, Nathalie M.
AU - Halberstadt, Adam L.
AU - Hartley, Rachel M.
AU - Hassaine, Ghérici
AU - Herrick-Davis, Katharine
AU - Hovius, Ruud
AU - Lacivita, Enza
AU - Lambe, Evelyn K.
AU - Leopoldo, Marcello
AU - Levy, Finn Olav
AU - Lummis, Sarah C.R.
AU - Marin, Philippe
AU - Maroteaux, Luc
AU - McCreary, Andrew C.
AU - Nelson, David L.
AU - Neumaier, John F.
AU - Newman-Tancredi, Adrian
AU - Nury, Hugues
AU - Roberts, Alexander
AU - Roth, Bryan L.
AU - Roumier, Anne
AU - Sanger, Gareth J.
AU - Teitler, Milt
AU - Sharp, Trevor
AU - Villalón, Carlos M.
AU - Vogel, Horst
AU - Watts, Stephanie W.
AU - Hoyer, Daniel
N1 - Funding Information:
This work was supported by Ministry of Defence [JFC7a/00018], the University of Birmingham and Celentyx Ltd. Centre national de la recherche scientifique (France), the Institut national de la santé et de la recherche médicale (France), University of Montpellier, Fondation pour la Recherche Médicale [Grant DPA20140629800] and l’Agence nationale de la recherche (France) [Grants ANR-11-BSV4-008-01 “SERO6COGNET,” ANR-12-BSV4-0008-01 “ADAMGUARD” and ANR-17-CE16-0013-01 “StopSero6TOR,” ANR-17-CE16-0010 “Sero6Dev”], France Alzheimer, Languedoc Roussillon region, Fondation Plan Alzheimer and Fondation Vaincre Alzheimer [Grant 12721 and LECMA FR-15072], National Institutes of Health National Institute on Drug Abuse [Grants T32 DA007287, P50 DA033935, and K05 DA020087], Banting and Best Canada Graduate Scholarship from the Canadian Institutes of Health Research, South-Eastern Norway Regional Health Authority, The Norwegian Council on Cardiovascular Diseases, The Research Council of Norway, The Kristian Gerhard Jebsen Foundation, Anders Jahre’s Foundation for the Promotion of Science, The Family Blix foundation, The Simon Fougner Hartmann Family Foundation and the University of Oslo, the European Research Council [Grant ERC-2014-StG PentaBrain], Consejo Nacional de Ciencia y Tecnología [Grant CONACyT, No. 219707], University of Melbourne, Hallmark initiative, National Health and Medical Research Council (Australia) [Grants APP1105284 and APP1105332], Alzheimer’s Association, and Royal Australian College of General Practitioners Ltd foundation (Australia). https://doi.org/10.1124/pr.118.015552.
Publisher Copyright:
© 2020 by The American Society for Pharmacology and Experimental Therapeutics.
PY - 2021/1
Y1 - 2021/1
N2 - 5-HT receptors expressed throughout the human body are targets for established therapeutics and various drugs in development. Their diversity of structure and function reflects the important role 5-HT receptors play in physiologic and pathophysiological processes. The present review offers a framework for the official receptor nomenclature and a detailed understanding of each of the 14 5-HT receptor subtypes, their roles in the systems of the body, and, where appropriate, the (potential) utility of therapeutics targeting these receptors.
AB - 5-HT receptors expressed throughout the human body are targets for established therapeutics and various drugs in development. Their diversity of structure and function reflects the important role 5-HT receptors play in physiologic and pathophysiological processes. The present review offers a framework for the official receptor nomenclature and a detailed understanding of each of the 14 5-HT receptor subtypes, their roles in the systems of the body, and, where appropriate, the (potential) utility of therapeutics targeting these receptors.
UR - http://www.scopus.com/inward/record.url?scp=85099115764&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099115764&partnerID=8YFLogxK
U2 - 10.1124/PR.118.015552
DO - 10.1124/PR.118.015552
M3 - Article
C2 - 33370241
AN - SCOPUS:85099115764
SN - 0031-6997
VL - 73
SP - 310
EP - 520
JO - Pharmacological Reviews
JF - Pharmacological Reviews
IS - 1
ER -